DEF: Fibrobiologics Sets Annual Meeting for June 22, 2026

Fibrobiologics, Inc. announced its Annual Meeting of Stockholders will be held virtually on June 22, 2026, to elect a director, ratify auditor appointment, approve stock issuance, and adopt a new equity plan.

Summary

• Fibrobiologics, Inc. is holding its Annual Meeting of Stockholders on June 22, 2026, virtually via the internet.
• Key proposals include the election of Pete O'Heeron as a Class III director, ratification of WithumSmith+Brown, PC as independent auditors for 2026, approval of the issuance of up to 2,272,728 shares of common stock upon exercise of warrants from a March 31, 2026, securities purchase agreement and up to 159,091 shares from an engagement letter dated November 10, 2025, and approval of the FibroBiologics, Inc. 2026 Equity and Incentive Compensation Plan.
• The company is providing access to proxy materials over the internet, with a Notice of Internet Availability of Proxy Materials to be mailed around May 5, 2026.
• The record date for determining stockholders entitled to vote is April 24, 2026.
• Pete O'Heeron, CEO and Chairperson, holds all 125 shares of Series C Preferred Stock, which carry 13,000 votes per share, subject to an irrevocable proxy to the Board, representing approximately 24% of the total votes.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant potential dilution from the proposed stock issuance and new equity plan, balanced by the procedural necessity of these actions for corporate governance and talent management.

Positives

• The company is holding its annual meeting to ensure continued corporate governance and strategic alignment.
• The proposed 2026 Equity and Incentive Compensation Plan aims to attract, motivate, and retain talent by linking compensation to long-term stockholder value.
• The Board will exercise its irrevocable proxy for Series C Preferred Stock to vote in favor of all proposals, indicating strong management support for the agenda.
• The company is seeking stockholder approval for the issuance of shares related to warrants, which is a standard procedure for Nasdaq compliance and future capital infusion potential.

Negatives

• The approval of Proposal 3 (stock issuance) will result in dilution of existing stockholders' ownership interests.
• If Proposal 3 is not approved, the company may face significant financial difficulties, including potential cash repayment obligations for outstanding warrants, which could reduce funds available for operations and investments.
• The proposed 2026 Equity and Incentive Compensation Plan, if approved, would increase the fully diluted overhang to 33.5%.

Risks

• Failure to approve Proposal 3 could lead to significant financial distress, including the need for emergency financing on unfavorable terms.
• The exercise of warrants and potential sale of shares could materially and adversely affect the market price of the company's common stock.
• The 2026 Equity and Incentive Compensation Plan, if approved, will increase the number of shares outstanding and could lead to significant dilution.
• The super voting rights of the Series C Preferred Stock, held by Pete O'Heeron and subject to an irrevocable proxy to the Board, could deter or delay a change in control.
• The company's business is in an evolving industry, and its success depends on developing and commercializing fibroblast-based therapies.

Future Outlook

The company is seeking stockholder approval for key proposals that will impact its equity structure and compensation plans, aiming to support talent retention and future growth. The approval of the stock issuance proposal is critical for avoiding potential financial repercussions.

Management Comments

• The Board will exercise the irrevocable proxy to cast 1,625,000 votes FOR each of the director nominees and the proposals described in this proxy statement, which constitutes approximately 24% of the total votes eligible to be cast at the Annual Meeting.
• The Board believes our future success depends in part on our ability to attract, motivate, and retain high quality employees and directors and that the ability to provide equity-based and incentive-based awards under the 2026 Plan is critical to achieving this success.
• We would be at a severe competitive disadvantage if we could not use share-based awards to recruit and compensate our employees and directors.
• The Board has determined that all members of the Board, except for Mr. O'Heeron, are independent directors for purposes of the rules of Nasdaq and the SEC.
• The Board believes that we should maintain our flexibility to select the Chairperson and CEO and determine the appropriate leadership structure, from time to time, based on criteria that are in our best interests and the best interests of our stockholders.

Industry Context

StockSavvy.ai notes that Fibrobiologics is operating in the highly competitive biotechnology sector, where robust equity incentive plans are crucial for attracting and retaining specialized talent. The proposed stock issuance and equity plan are standard for companies at this stage seeking to manage liquidity and align employee incentives with shareholder value.

Comparison to Industry Standards

• The proposed 2026 Equity and Incentive Compensation Plan includes an 'evergreen' provision, automatically increasing the share pool annually by up to 4% of outstanding shares, a common practice in the biotech industry to ensure long-term equity availability.
• The non-employee director compensation structure, including annual retainers and equity grants (initial grant of 2,200 shares and annual grant of 1,100 stock options), aligns with typical compensation models for boards of directors in publicly traded companies.
• The company's burn rate for equity awards has decreased from 13.07% in 2023 to 3.11% in 2025, indicating a more conservative approach to equity dilution, which is generally viewed favorably by investors.
• The proposed total initial shares under the 2026 Plan (2,339,199) represent approximately 33.5% of the fully diluted shares outstanding as of April 24, 2026, which is a significant but not unusual level of potential dilution for a growth-stage biotech company.

Management Changes

Corporate Governance

Related Party Transactions

• On November 18, 2025, Fibrobiologics entered into a securities purchase agreement with Golden Knight Incorporated, LP (GK), a 5% stockholder, issuing shares and pre-funded warrants, and subsequently issued warrants to GK. GK also exercised pre-funded warrants and issued a $400,000 note receivable to GK on January 14, 2026.

Stakeholder Impact

• Shareholders will experience potential dilution if warrants are exercised and shares are issued under Proposal 3 and the new equity plan.
• Employees and directors will have opportunities for equity-based compensation under the proposed 2026 Equity and Incentive Compensation Plan, intended to align their interests with long-term stockholder value.
• The company's ability to fund operations and pursue growth opportunities could be impacted by the outcome of Proposal 3, particularly if cash repayment of warrants is required.

Next Steps

• Stockholders to vote on the four proposals at the Annual Meeting on June 22, 2026.
• If Proposal 3 is not approved, the company will be required to continue seeking stockholder approval every 90 days.
• If the 2026 Equity and Incentive Compensation Plan is approved, it will become effective on the date of the Annual Meeting, and no further grants will be made under the 2022 Stock Plan.
• Final voting results will be published in a Form 8-K within four business days after the Annual Meeting.

Key Dates

Recommendation

The filing outlines standard corporate governance procedures and proposals for an annual meeting. While the proposed stock issuance and equity plan carry dilution risks, they are presented as necessary for Nasdaq compliance and talent retention. The strong voting bloc controlled by the Board via Series C Preferred Stock suggests these proposals are likely to pass. Investors should monitor the impact of potential dilution and the company's progress in its clinical trials and financing efforts.

Keywords

Fibrobiologics, DEF 14A, Proxy Statement, Annual Meeting, Stockholder Vote, Director Election, Auditor Ratification, Stock Issuance, Warrants, Equity Compensation Plan, Nasdaq Listing Rule, Corporate Governance